Benefits
Multiple myeloma chemo immunomodulation NCT00970021 (PMC4312620)
PMC4312620 — randomized double-blind clinical study in multiple myeloma patients undergoing high-dose chemotherapy + autologous stem cell transplantation. AndoSan™ AbM-based mushroom extract 60 ml/day for ~7 weeks vs placebo. Primary endpoints: cytokine/chemokine/growth factor changes + immune gene expression + stem cell mononuclear subsets. Foundational clinical evidence in cancer adjunct context.
NSCLC perioperative immune modulation (PMC12839190 multicenter pilot)
PMC12839190 — randomized double-blind placebo-controlled multicenter pilot in non-small-cell lung cancer (NSCLC) patients undergoing curative resection. Multivitamin complex containing Agaricus blazei. RESULTS: significantly better preservation of T cells (P=0.026) + B cells (P=0.001) + greater reduction in monocytes (P=0.031) in treatment group. Favorable immune modulation.
NLRP3 inflammasome activation (PMID 22844468)
PMID 22844468 — AbM water extracts ENHANCE IL-1β production + ACTIVATE NLRP3 INFLAMMASOME in human THP-1 macrophages. Mechanism: pattern recognition receptor signaling. Distinguishing immunomodulatory pathway. Foundational mechanism for anti-tumor immune activation.
IBD cytokine modulation (PMID 21129005 ulcerative colitis + Crohn's)
Førland 2011 PMID 21129005 (Scand J Immunol 73:66-75) — AbM extract effect on cytokine + calprotectin expression in ULCERATIVE COLITIS + CROHN'S DISEASE patients. Significantly REDUCED cytokines MIP-1β, MCP-1, IL-8, IL-1β, G-CSF, IL-17, GM-CSF, IL-2 vs day 0. Foundational IBD evidence — anti-inflammatory immunomodulation.
Antitumor mechanism review (PMC7285126)
PMC7285126 — review of AbM + Hericium erinaceus + Grifola frondosa antitumor + anti-inflammatory + antiallergic effects. AbM antitumor mechanisms: direct (apoptosis, antimutagenesis, metastatic suppression) + indirect (inhibited neovascularization, Th1 cytotoxic cell tumor migration, MΦ NO production, NK cell activation, enhanced chemotherapeutic effects + reduced side effects).
Beta-glucan antitumor mechanism (Itoh 1994)
Itoh 1994 (Jpn J Pharmacol 66:265-271) — (1→6)-β-D-glucan-protein complex (FIII-2-b) isolated from AbM 'Himematsutake' showed inhibitory action on Meth A fibrosarcoma in mice. Foundational beta-glucan immunomodulation mechanism. Mushroom common name: Himematsutake (Japanese).
HONEST mixed pro-/anti-inflammatory effects
HONEST framing: AbM has DIFFERENTIAL effects — pro-inflammatory cytokine production in human monocytes + endothelial cells in vitro (Bernardshaw 2005 PMID 17091395) but IMMUNOSUPPRESSIVE effects with oral intake in healthy volunteers + IBD patients. Mechanism: context-dependent immunomodulation. Important for clinical translation interpretation.
Mechanism of action
β-(1→6)-D-glucan-protein complex (FIII-2-b)
Itoh 1994 — (1→6)-β-D-glucan-protein complex isolated from AbM. Mechanism: pattern recognition receptor (Dectin-1) binding → macrophage activation → tumor inhibition.
NLRP3 inflammasome activation + IL-1β
PMID 22844468 — AbM activates NLRP3 inflammasome in human THP-1 macrophages → IL-1β production. Mechanism: innate immunity activation → anti-tumor immune response.
Th1 cytotoxic cell + NK cell activation
AbM induces Th1 cytotoxic cell tumor migration + macrophage NO production + NK cell activation (PMC7285126 review). Mechanism: cellular immunity enhancement supporting anti-tumor response.
Anti-angiogenic + anti-metastatic
Inhibits tumor neovascularization + metastatic suppression. Mechanism: indirect anti-tumor activity complementing direct apoptosis effects.
Chemotherapy enhancement + side-effect reduction
Enhances chemotherapeutic drug effects + reduces side effects (PMC7285126). Mechanism: immune restoration during chemotherapy + drug sensitization.
Context-dependent immunomodulation
Pro-inflammatory in vitro (monocytes, endothelial cells) but IMMUNOSUPPRESSIVE in vivo (IBD patients, healthy volunteers oral intake). Mechanism: route-of-administration + tissue-specific effects. Distinguishing dual mechanism.
Clinical trials
Phase 2 randomized double-blind quadruple-masked trial (NCT00970021). Sponsor: Ullevaal University Hospital. STATUS: COMPLETED.
Multiple myeloma patients undergoing high-dose chemotherapy + autologous stem cell transplantation. AndoSan™ AbM extract 60 ml/day or placebo from start of stem cell mobilizing treatment until 1 week after end of aplasia after high-dose melphalan. Duration ~7 weeks.
Primary endpoints: cytokine/chemokine/growth factor serum changes + immune gene expression + stem cell harvest mononuclear cell subsets. Secondary: clinical response, neutropenia time, fever days, IV antibiotic days, time to new treatment, overall survival, QoL. Foundational randomized evidence in oncology adjunct context.
Randomized double-blind placebo-controlled multicenter pilot trial (PMC12839190).
Non-small-cell lung cancer (NSCLC) patients undergoing curative surgical resection. Multivitamin complex containing Agaricus blazei vs placebo perioperatively.
Significantly better preservation of T cells (P=0.026) + B cells (P=0.001) + greater reduction in monocytes (P=0.031) in treatment group. NO significant differences in cytokine levels, BMI, ECOG status, or patient-reported outcomes. Conclusion: AbM-containing complex may contribute to favorable immune modulation in NSCLC curative surgery.
Clinical study (Førland DT, Johnson E, Saetre L, Lyberg T, Lygren I, Hetland G 2011, Scand J Immunol 73:66-75, doi:10.1111/j.1365-3083.2010.02477.x).
Ulcerative colitis + Crohn's disease patients. AndoSan AbM extract oral intake.
Significantly REDUCED cytokines MIP-1β, MCP-1, IL-8, IL-1β + G-CSF, IL-17, GM-CSF, IL-2 in plasma vs day 0 prior to AndoSan intake. Crohn's disease group most responsive. Foundational anti-inflammatory immunomodulation evidence in IBD patients.
About this ingredient
AGARICUS BLAZEI MURILL (AbM, recently reclassified as Agaricus subrufescens) is a BRAZILIAN + EASTERN MEDICINAL MUSHROOM with Japanese name 'HIMEMATSUTAKE' (means 'princess matsutake'). Documented since 1980s in scientific studies for ANTITUMOR + ANTI-INFLAMMATORY + ANTIALLERGIC effects. Active compounds: PROTEOGLYCANS, β-(1→6)-D-GLUCAN-PROTEIN COMPLEX (FIII-2-b per Itoh 1994), POLYSACCHARIDES. PIVOTAL CLINICAL EVIDENCE: NCT00970021 PMC4312620 — randomized double-blind phase 2 trial (Ullevaal University Hospital). Multiple myeloma patients undergoing high-dose chemotherapy + autologous stem cell transplantation. AndoSan™ AbM-based mushroom extract 60 ml/day for ~7 weeks vs placebo. Primary endpoints: cytokine/chemokine/growth factor changes + immune gene expression + stem cell mononuclear cell subsets. Status: COMPLETED. PMC12839190 — randomized double-blind placebo-controlled multicenter pilot in NSCLC perioperative immune modulation. Multivitamin complex containing AbM. RESULTS: significantly better preservation of T cells (P=0.026) + B cells (P=0.001) + greater reduction in monocytes (P=0.031). FØRLAND DT et al. 2011 PMID 21129005 (Scand J Immunol 73:66-75, doi:10.1111/j.1365-3083.2010.02477.x) — UC + Crohn's patients on AndoSan: significantly REDUCED cytokines MIP-1β, MCP-1, IL-8, IL-1β, G-CSF, IL-17, GM-CSF, IL-2 vs day 0. PMID 22844468 — AbM water extracts ENHANCE IL-1β production + ACTIVATE NLRP3 INFLAMMASOME in human THP-1 macrophages. ITOH 1994 (Jpn J Pharmacol 66:265-271) — (1→6)-β-D-glucan-protein complex (FIII-2-b) isolated from AbM 'Himematsutake' showed inhibitory action on Meth A fibrosarcoma in mice. PMC7285126 review of AbM + HE + GF antitumor mechanisms. BERNARDSHAW 2005 PMID 17091395 — AbM differentially stimulates pro-inflammatory cytokine production in human monocytes + endothelial cells in vitro.
MECHANISMS: β-(1→6)-D-GLUCAN-PROTEIN COMPLEX (FIII-2-b) — Dectin-1 PRR binding + macrophage activation; NLRP3 INFLAMMASOME activation + IL-1β production (innate immunity); TH1 CYTOTOXIC CELL + NK CELL activation (cellular immunity); ANTI-ANGIOGENIC + ANTI-METASTATIC effects (indirect anti-tumor); CHEMOTHERAPY ENHANCEMENT + side-effect reduction; CONTEXT-DEPENDENT IMMUNOMODULATION (pro-inflammatory in vitro vs immunosuppressive in vivo IBD/healthy oral intake). EVIDENCE: 3/5 reflects: (1) NCT00970021 multiple myeloma phase 2 RCT, (2) PMC12839190 NSCLC perioperative multicenter pilot RCT, (3) FØRLAND 2011 IBD cytokine modulation evidence, (4) PMID 22844468 NLRP3 inflammasome mechanism, (5) PMC7285126 antitumor mechanism comprehensive review, (6) ITOH 1994 β-glucan-protein complex preclinical mechanism, (7) HONEST FRAMING — context-dependent immunomodulation (pro-inflammatory in vitro vs immunosuppressive in vivo), (8) ANDOSAN BRANDED extract has dedicated research program, (9) MULTIPLE INDICATIONS supported (oncology adjunct, IBD adjunct, immune modulation), (10) higher-evidence than typical 'medicinal mushroom' due to dedicated Norwegian/Hetland research group RCTs. SAFETY: Generally favorable — extensive AndoSan clinical use + Brazilian/Asian traditional use record. Best positioned as: (a) ONCOLOGY IMMUNE MODULATION ADJUNCT (NCT00970021 multiple myeloma + PMC12839190 NSCLC evidence), (b) IBD ANTI-INFLAMMATORY adjunct (Førland 2011 cytokine reduction), (c) IMMUNE FUNCTION SUPPORT (NLRP3 + Th1 + NK mechanisms), (d) CHEMOTHERAPY-ENHANCED + side-effect reduced support (mechanism evidence), (e) ANDOSAN branded extract preferable for trial-matched formulation, (f) AUTOIMMUNE conditions: caution due to immune activation, (g) IMMUNOCOMPROMISED: caution (immunomodulatory activity), (h) PREGNANCY: limited specific data, (i) higher-evidence than typical immune mushroom due to multi-RCT clinical evidence. Honest framing: Agaricus blazei Murill has SOLID EMERGING EVIDENCE for oncology adjunct + IBD anti-inflammatory applications — NCT00970021 multiple myeloma RCT + PMC12839190 NSCLC perioperative immune modulation + Førland 2011 IBD cytokine modulation are methodologically rigorous evidence base. CONTEXT-DEPENDENT IMMUNOMODULATION is genuinely distinguishing — pro-inflammatory in vitro vs immunosuppressive in vivo with oral intake. AndoSan branded extract (Norwegian/Hetland research group) supports trial-matched formulation. Himematsutake (princess matsutake) Japanese traditional name. β-(1→6)-D-glucan-protein complex (FIII-2-b) is biochemically distinguishing among medicinal mushroom polysaccharides. Reasonable oncology adjunct + IBD support based on multi-trial evidence — particularly compelling for chemotherapy patients seeking immune support or IBD patients seeking anti-inflammatory adjunct. Caution in autoimmune conditions due to immune activation potential.